The US FDA has approved a fourth product via its new National Priority Voucher Programme — a 7.2 mg dose of Novo Nordisk’s weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD. This time the time from approval to filing was just 54 days according to the agency.
“The new FDA is moving with unprecedented efficiency on products that advance national priorities,” said FDA Commissioner Dr Martin Makary. “Today’s approval is another demonstration of what the FDA can accomplish when we try bold new things.”
Tech talent comes to healthcare
In San Francisco a few weeks ago, I caught up with Nworah Ayogu, partner at Thrive Capital. Thrive had recently announced that it raised a